ERBB2 and malignant colon neoplasm: The monoclonal antibody trastuzumab (Herceptin®), which targets the extracellular domain of HER2, has been shown to inhibit proliferation in HER2-expressing cells, and inhibition of NF-κB has been shown to enhance these anti-proliferative effects in breast and colon cancer cells [29], [50].